EntryPoint Capital LLC Has $478,000 Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

EntryPoint Capital LLC grew its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 137.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 26,022 shares of the biopharmaceutical company’s stock after purchasing an additional 15,052 shares during the quarter. EntryPoint Capital LLC’s holdings in ACADIA Pharmaceuticals were worth $478,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Quest Partners LLC boosted its stake in ACADIA Pharmaceuticals by 42.3% in the third quarter. Quest Partners LLC now owns 3,520 shares of the biopharmaceutical company’s stock valued at $54,000 after acquiring an additional 1,047 shares during the last quarter. KBC Group NV lifted its stake in shares of ACADIA Pharmaceuticals by 67.0% in the 4th quarter. KBC Group NV now owns 5,093 shares of the biopharmaceutical company’s stock valued at $93,000 after purchasing an additional 2,044 shares during the period. Advisors Asset Management Inc. boosted its position in shares of ACADIA Pharmaceuticals by 13.4% in the 3rd quarter. Advisors Asset Management Inc. now owns 21,087 shares of the biopharmaceutical company’s stock worth $324,000 after purchasing an additional 2,499 shares during the last quarter. R Squared Ltd acquired a new stake in shares of ACADIA Pharmaceuticals during the fourth quarter worth $47,000. Finally, Victory Capital Management Inc. increased its holdings in ACADIA Pharmaceuticals by 2.9% in the third quarter. Victory Capital Management Inc. now owns 97,130 shares of the biopharmaceutical company’s stock valued at $1,494,000 after purchasing an additional 2,708 shares during the last quarter. Institutional investors and hedge funds own 96.71% of the company’s stock.

Analyst Upgrades and Downgrades

ACAD has been the topic of a number of recent analyst reports. Guggenheim cut ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $23.00 to $20.00 in a report on Friday, January 3rd. HC Wainwright restated a “buy” rating and set a $27.00 price objective on shares of ACADIA Pharmaceuticals in a report on Thursday, February 27th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $28.00 target price on shares of ACADIA Pharmaceuticals in a report on Thursday, February 27th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of ACADIA Pharmaceuticals in a report on Tuesday, February 11th. They issued a “hold” rating and a $22.00 price target for the company. Finally, Morgan Stanley restated an “equal weight” rating and issued a $20.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Friday, March 7th. Eight analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $23.93.

Insider Buying and Selling

In related news, Director Elizabeth A. Garofalo sold 4,919 shares of the company’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $18.23, for a total transaction of $89,673.37. Following the sale, the director now owns 17,595 shares in the company, valued at approximately $320,756.85. This represents a 21.85 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last 90 days, insiders sold 6,167 shares of company stock worth $114,583. 28.30% of the stock is owned by insiders.

ACADIA Pharmaceuticals Stock Down 0.7 %

NASDAQ:ACAD opened at $17.11 on Wednesday. The company has a market cap of $2.85 billion, a P/E ratio of 21.94 and a beta of 0.43. ACADIA Pharmaceuticals Inc. has a twelve month low of $14.15 and a twelve month high of $20.68. The business has a 50 day moving average price of $18.36 and a two-hundred day moving average price of $17.02.

ACADIA Pharmaceuticals Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.